Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Published: 14-02-2019| Version 1 | DOI: 10.17632/v7x4f88n63.1
Contributor:
Huijuan Wang

Description

Supplemental Table. Tumour responses in patients with uncommon EGFR mutations. Single mutations, G719X, S768I, L861Q; Complex mutations, G719X+S768I/+L861Q; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; P-value based on the Chi-square test.

Files